Industry
Biotechnology
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Loading...
Open
2.82
Mkt cap
250M
Volume
1M
High
2.95
P/E Ratio
-2.08
52-wk high
8.33
Low
2.68
Div yield
N/A
52-wk low
1.50
Portfolio Pulse from Benzinga Newsdesk
September 25, 2024 | 1:13 pm
Portfolio Pulse from Benzinga Newsdesk
September 03, 2024 | 8:04 pm
Portfolio Pulse from Benzinga Insights
September 03, 2024 | 5:00 pm
Portfolio Pulse from Benzinga Newsdesk
September 03, 2024 | 3:10 pm
Portfolio Pulse from Benzinga Newsdesk
September 03, 2024 | 12:25 pm
Portfolio Pulse from Benzinga Insights
August 14, 2024 | 2:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 11:00 am
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 3:53 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 9:12 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.